Revolution Medicines, Inc. $RVMD Shares Bought by Eagle Health Investments LP

Eagle Health Investments LP boosted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 3.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 119,464 shares of the company’s stock after purchasing an additional 3,564 shares during the period. Revolution Medicines makes up approximately 2.0% of Eagle Health Investments LP’s portfolio, making the stock its 18th biggest holding. Eagle Health Investments LP owned 0.06% of Revolution Medicines worth $11,618,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Indiana Trust & Investment Management Co purchased a new stake in shares of Revolution Medicines in the fourth quarter worth about $32,000. Global Retirement Partners LLC raised its position in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares in the last quarter. Torren Management LLC acquired a new position in Revolution Medicines in the fourth quarter valued at approximately $33,000. Arax Advisory Partners acquired a new position in Revolution Medicines in the fourth quarter valued at approximately $38,000. Finally, Darwin Wealth Management LLC purchased a new stake in Revolution Medicines in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Stock Down 0.6%

Shares of RVMD opened at $188.07 on Tuesday. The firm has a market cap of $39.98 billion, a P/E ratio of -26.60 and a beta of 1.37. Revolution Medicines, Inc. has a 12 month low of $34.00 and a 12 month high of $194.56. The stock’s 50 day moving average is $169.74 and its two-hundred day moving average is $132.87. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the business earned ($1.13) earnings per share. Analysts predict that Revolution Medicines, Inc. will post -7.91 earnings per share for the current fiscal year.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the transaction, the director directly owned 21,656 shares in the company, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jack Anders sold 20,000 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $20,749,870.77. The trade was a 13.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 132,497 shares of company stock valued at $21,470,486 in the last three months. Company insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

RVMD has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $195.00 price objective on shares of Revolution Medicines in a research note on Monday, July 6th. Stifel Nicolaus reiterated a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Royal Bank Of Canada increased their price target on shares of Revolution Medicines from $165.00 to $182.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Wedbush raised their price target on shares of Revolution Medicines from $181.00 to $192.10 and gave the company an “outperform” rating in a research report on Thursday. Finally, Evercore reaffirmed an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Revolution Medicines has an average rating of “Moderate Buy” and an average target price of $144.67.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.